News
DERM
4.420
-2.21%
-0.100
Ocular Therapeutix (OCUL) Reports Q3 Loss, Lags Revenue Estimates
NASDAQ · 1d ago
Weekly Report: what happened at DERM last week (1102-1106)?
Weekly Report · 1d ago
Weekly Report: what happened at DERM last week (1026-1030)?
Weekly Report · 11/02 10:11
Journey Medical Price Target Maintained With a $13.00/Share by HC Wainwright & Co.
Dow Jones · 10/26 10:38
Journey Medical Corp (DERM) Gets a Buy from H.C. Wainwright
TipRanks · 10/26 10:37
HC Wainwright & Co. Reiterates Buy on Journey Medical, Maintains $13 Price Target
Benzinga · 10/26 10:28
Weekly Report: what happened at DERM last week (1019-1023)?
Weekly Report · 10/26 10:11
Korro Bio, Inc. (KRRO) Surges 29.7%: Is This an Indication of Further Gains?
NASDAQ · 10/23 09:47
Weekly Report: what happened at DERM last week (1012-1016)?
Weekly Report · 10/19 10:11
Weekly Report: what happened at DERM last week (1005-1009)?
Weekly Report · 10/12 10:16
Weekly Report: what happened at DERM last week (0928-1002)?
Weekly Report · 10/05 10:16
Weekly Report: what happened at DERM last week (0921-0925)?
Weekly Report · 09/28 10:11
H.C. Wainwright Remains a Buy on Journey Medical Corp (DERM)
TipRanks · 09/22 09:45
Weekly Report: what happened at DERM last week (0914-0918)?
Weekly Report · 09/21 10:11
Journey Medical: A Small Pharma With A Large Growth Opportunity
Seeking Alpha · 09/19 14:25
Weekly Report: what happened at DERM last week (0907-0911)?
Weekly Report · 09/14 10:16
Weekly Report: what happened at DERM last week (0831-0904)?
Weekly Report · 09/07 10:10
Weekly Report: what happened at DERM last week (0824-0828)?
Weekly Report · 08/31 10:17
ELTP vs. DERM: Which Specialty Pharmaceutical Stock Is the Better Buy?
NASDAQ · 08/25 15:20
Weekly Report: what happened at DERM last week (0817-0821)?
Weekly Report · 08/24 10:17
More
Webull provides a variety of real-time DERM stock news. You can receive the latest news about Journey Medical Corp through multiple platforms. This information may help you make smarter investment decisions.
About DERM
Journey Medical Corporation is a commercial-stage pharmaceutical company. The Company is focused on selling and marketing of the United States Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the United States. Its marketed products, which have been approved FDA for sale in the United States, include Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm Cream and Solution, Targadox, and Luxamend. Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis. Accutane is an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne. Targadox is an oral doxycycline drug for adjunctive therapy for severe acne. Luxamend is a water-based emulsion formulated to provide moist healing environment.